Molecular pharmacology of the ovine melatonin receptor: Comparison with recombinant human MT1 and MT2 receptors

Biochemical Pharmacology

Volumn 67, Issue 4, 2004, Pages 667-677

  Mailliet, François ^a,b   Audinot, Valérie ^b   Malpaux, Benoit ^a   Bonnaud, Anne ^b   Delagrange, Philippe ^c   Migaud, Martine ^a   Barrett, Perry ^d   Viaud Massuard, Marie Claude ^e   Lesieur, Daniel ^f   Lefoulon, François ^c   Renard, Pierre ^c   Boutin, Jean A ^b  

^a UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d ROWETT RESEARCH INSTITUTE   (United Kingdom)

^e UNIVERSITÉ DE TOURS   (France)

^f Universite de Lille   (France)

Author keywords

CHO cells; Melatonin; Molecular pharmacology; Pars tuberalis; Recombinant human melatonin receptors; Recombinant ovine melatonin receptor

Indexed keywords

MELATONIN RECEPTOR; RECOMBINANT OVINE MELATONIN RECEPTOR 1; RECOMBINANT OVINE MELATONIN RECEPTOR 2; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHO CELL; CIRCADIAN RHYTHM; CONTROLLED STUDY; DNA TRANSFECTION; HYPOPHYSIS PARS TUBERALIS; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY;

EID: 9144232229     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.09.037     Document Type: Article

References (51)

1. Dollins A.B., Zhdanova I.V., Wurtman R.J., Lynch H.J., Deng M.H. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc. Natl. Acad. Sci. U.S.A. 91:1994;1824-1828.
2. Hagan R.M., Oakley N.R. Melatonin comes of age? Trends Pharmacol. Sci. 1:1995;81-83.
3. Morgan P.J., Barrett P., Howell H.E., Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int. 24:1994;101-146.
4. Dubocovich M.L. Pharmacology and function of melatonin receptors. FASEB J. 2:1988;2765-2773.
5. Dubocovich M.L. Melatonin receptors: are there multiple subtypes? Trends Pharmacol. Sci. 16:1995;50-56.
6. Ebisawa T., Karne S., Lerner M.R., Reppert S.M. Expression cloning of a high-affinity Melatonin receptor from Xenopus dermal melanophores. Proc. Natl. Acad. Sci. U.S.A. 91:1994;6133-6137.
7. Reppert S.M., Weaver D.R., Ebisawa T. Cloning and characterization of a mammalian Melatonin receptor that mediates reproductive and circadian responses. Neuron. 13:1994;1177-1185.
8. Reppert S.M., Godson C., Mahle C.D., Weaver D.R., Slaugenhaupt S.A., Gusella J.F. Molecular characterization of a second Melatonin receptor expressed in human retina and brain: the Mel1b Melatonin receptor. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8734-8738.
9. Reppert S.M., Weaver D.R., Cassone V.M., Godson C., Kolawkoski L.F. Jr. Melatonin receptor for the birds: molecular analysis of two subtypes differentially expressed in chick brain. Neuron. 15:1995;1003-1015.
10. Roca A.L., Godson C., Weaver D.R., Reppert S.M. Structure, characterization and expression of the gene encoding the mouse Mel1a melatonin receptor. Endocrinology. 137:1996;3469-3477.
11. Jockers R., Petit L., Lacroix I., de Coppet P., Barrett P., Morgan P.J., Guardiola B., Delagrange P., Marullo S., Strosberg A.D. Novel isoforms of Mel1c Melatonin receptors modulating intracellular cyclic guanosine 3′,5′-monophosphate levels. Mol. Endocrinol. 11:1997;1070-1081.
12. Sugden D., Pickering H., Teh M.T., Garratt P.J. Melatonin receptor pharmacology: toward subtype specificity. Biol Cell. 89:1997;531-537.
13. 2 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 367:2003;553-561.
14. 1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 355:1997;365-375.
15. Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., Fauchere J.L., Delagrange P., Canet E., Boutin J.A. Identification of the melatonin-binding Site MT3 as the Quinone Reductase 2. J. Biol. Chem. 275:2000;31311-31317.
16. Nosjean O., Nicolas J.P., Klupsch F., Delagrange P., Canet E., Boutin J.A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem. Pharmacol. 61:2001;1369-1379.
17. Morgan P.J. The Pars Tuberalis: the missing link in the photoperiodic regulation of prolactin secretion? J. Neuroendocrinol. 12:2001;287-295.
18. Depreux P., Lesieur D., Ait Mansour H., Morgan P., Howell H.E., Renard P., Caignard D.H., Pfeiffer B., Delagrange P., Guardiola B., Yous S., Demarque A., Adam G., Andrieux J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J. Med. Chem. 37:1994;3231-3239.
19. Leclerc V., Fourmaintraux E., Depreux P., Lesieur D., Morgan P.J., Howell H.E., Renard P., Caignard D.H., Pfeiffer B., Delagrange P., Guardiola-Lemaître B., Andrieux J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. Bioorg. Med. Chem. 6:1998;1875-1887.
20. Andrieux J, Houssin R, Yous S, Renard P, Lesieur D, Guardiola- Lemaître B. European Patent Application EP447285; September 18, 1991.
21. Lesieur D, Depreux P, Leclerc V, Delagrange P, Renard P, Guardiola-Lemaître B. European Patent Application EP745584; December 4, 1996.
22. Charton I., Mamai A., Bennejean C., Renard P., Delagrange P., Morgan P.J., Howell H.E., Gourdel-Martin M.E., Viaud M.C., Guillaumet G. Synthesis and biological activity of new melatonin receptor ligands. Pharm. Pharmacol. Commun. 6:2000;49-60.
23. Wallez V., Durieux-Poissonnier S., Chavatte P., Boutin J.A., Audinot V., Nicolas J.P., Bennejean C., Delagrange P., Renard P., Lesieur D. Synthesis and structure-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands. J. Med. Chem. 45:2002;2788-2800.
24. Lesieur D, Yous S, Descamps-François C, Lefoulon F, Guillaumet G, Viaud MC, Bennejean C, Delagrange P, Renard P. European Patent Application EP1038863; September 27, 2000.
25. Lesieur D, Leclerc V, Delagrange P, Depreux P, Ait Mansour H, Renard P. European Patent Application EP708099; April 24, 1996.
26. Guillaumet G, Viaud MC, Mamai A, Charton I, Renard P, Bennejean C, Guardiola-Lemaître B. International Patent Application WO9852935; November 26, 1998.
27. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
28. Dutton C.M., Paynton C., Sommer S.S. General method for amplifying regions of very high G+C content. Nucleic Acids Res. 21:1993;2953-2954.
29. Barrett P., Conway S., Jockers R., Strosberg A.D., Guardiola- Lemaître B., Delagrange P., Morgan P.J. Cloning and functional analysis of a polymorphic variant of the ovine Mel 1a Melatonin receptor. Biochim. Biophys. Acta. 1356:1997;299-307.
30. Bradford M. A rapid and sensitive method for the quantification of micrograms quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
31. Piketty V., Pelletier J. Melatonin receptor in the lamb pars tuberalis/median eminence throughout the day. Neuroendocrinology. 58:1993;359-365.
32. Scatchard G. The attraction of protein for small molecules and ions. Ann. N.Y. Acad. Sci. 51:1949;660-672.
33. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
34. Conway S., Canning S.J., Barrett P., Guardiola-Lemaître B., Delagrange P., Morgan P.J. The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta Melatonin receptor. Biochem. Biophys. Res. Commun. 239:1997;418-423.
35. Pickering H., Sword S., Vonhoff S., Jones R., Sugden D. Analogues of diverse structure are unable to differentiate native Melatonin receptors in the chicken retina, sheep pars tuberalis and Xenopus melanophores. Br. J. Pharmacol. 119:1996;379-387.
36. 125I ]iodomelatonin binding sites in chicken brain and sheep pars tuberalis Brain Res. 539:1991;151-154.
37. Morgan P.J., Williams L.M., Davidson G., Lawson W., Howell E. Melatonin receptors on ovine Pars Tuberalis: characterization and autoradiographical localization. J. Neuroendocrinol. 1:1989;1-4.
38. Dubocovich ML, Cardinali DP, Delagrange P, Krause DN, Strosberg D, Sugden D, Yocca FD. Melatonin receptors. In: The IUPHAR compendium of receptor characterization and classification. London: IUPHAR Media; 2000. p. 270-7.
39. Zisapel N., Laudon M. A novel melatonin antagonist affects melatonin-mediated processes in vitro and in vivo. Eur. J. Pharmacol. 136:1987;259-260.
40. Laudon M., Yaron Z., Zisapel N. N-(2,4-Dinitrophenyl)-5- methoxytryptamine, a novel melatonin antagonist: effects on sexual maturation of the male and female rat and on oestrous cycles of the female rat. J. Endocrinol. 116:1988;43-53.
41. Pevet P., Masson-Pevet M., Chantegrel J., Marsura A., Luu-Duc C., Claustrat B. Failure of N-(2,4-dinitrophenyl)-5-methoxytryptamine (a putative melatonin antagonist) and of N-(3,5-dinitrophenyl)-5-methoxytryptamine to prevent the effects of injections of melatonin in the late afternoon on testicular activity of the golden hamster. J. Endocrinol. 123:1989;243-247.
42. Nowak J.Z., Kazula A., Golembiowska K. Melatonin increases serotonin N-acetyltransferase activity and decreases dopamine synthesis in light-exposed chick retina: in vivo evidence supporting melatonin-dopamine interaction in retina. J. Neurochem. 59:1992;1499-1505.
43. Sugden D. Effect of putative melatonin receptor antagonists on melatonin-induced pigment aggregation in isolated Xenopus laevis melanophores. Eur. J. Pharmacol. 213:1992;405-408.
44. Briard N., Dutour A., Epelbaum J., Sauze N., Slama A., Oliver C. Species differences between male rat and ram pituitary somatostatin receptors involved in the inhibition of growth hormone secretion. Eur. J. Endocrinol. 137:1997;545-555.
45. Paquet J.L., Luccarini J.M., Fouchet C., Defrene E., Loillier B., Robert C., Belichard P., Cremers B., Pruneau D. Pharmacological characterization of the bradykinin B2 receptor: inter-species variability and dissociation between binding and functional responses. Br. J. Pharmacol. 126:1999;1083-1090.
46. Molderings G.J., Bonisch H., Bruss M., Likungu J., Gothert M. Species-specific pharmacological properties of human alpha(2A)-adrenoceptors. Hypertension. 36:2000;405-410.
47. Ireland-Denny L., Parihar A.S., Miller T.R., Kang C.H., Krueger K.M., Esbenshade T.A., Hancock A.A. Species-related pharmacological heterogeneity H(3) receptors. Eur. J. Pharmacol. 433:2001;141-150.
48. Conway S., Canning S.J., Howell H.E., Mowat E.S., Barrett P., Drew J.E., Delagrange P., Lesieur D., Morgan P.J. Characterisation of human melatonin MT(1) and MT(2) receptors by CRE-luciferase reporter assay. Eur. J. Pharmacol. 390:2000;15-24.
49. 1a Melatonin receptor expressed in Yeast reveals domains important for receptor function. Biochem. Biophys. Res. Commun. 249:1998;531-536.
50. Gubitz A.K., Reppert S.M. Chimeric and point-mutated receptors reveal that a single glycine residue in transmembrane domain 6 is critical for high affinity melatonin binding. Endocrinology. 141:2000;1236-1244.
51. Ting K.N., Blaylock N.A., Sugden D., Delagrange P., Scalbert E., Wilson V.G. Molecular and pharmacological evidence for MT1 Melatonin receptor subtype in the tail artery of juvenile Wistar rats. Br. J. Pharmacol. 127:1999;987-995.